Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketorocaine LM Kit is an unapproved combination pharmaceutical kit developed by Asclemed USA for peri-procedural analgesia and local or regional anesthesia. It contains four small-molecule active ingredients: ketorolac tromethamine, lidocaine hydrochloride, bupivacaine hydrochloride, and povidone-iodine. The pharmacology reflects the combined actions of a nonsteroidal anti-inflammatory drug and local anesthetics: ketorolac reduces prostaglandin synthesis through cyclooxygenase inhibition, while lidocaine and bupivacaine block voltage-gated sodium channels to inhibit nerve impulse conduction; povidone-iodine serves as a topical antiseptic adjunct. Reported routes associated with the kit include infiltration, intramuscular, intravenous, and topical administration. Available context indicates that the product has not been found by the FDA to be safe and effective and that its labeling has not been approved.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketorocaine lm kit.